Navigation Links
Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results

SAN DIEGO, May 9 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA), a company focused on the discovery and development of small- molecule therapeutics for the treatment of HIV, cancer and inflammatory diseases, including gout, today announced that John W. Beck has been appointed Senior Vice President, Finance and Operations and Chief Financial Officer effective May 27, 2008. He will resign from our board of directors shortly thereafter. The Company also reported recent accomplishments and financial results for the first quarter ended March 31, 2008.

Appointment of John W. Beck as Chief Financial Officer

"We are extremely pleased to welcome John Beck as the new Chief Financial Officer of Ardea," said Barry D. Quart, PharmD, Ardea Biosciences' President and CEO. "John has served as a member of our board of directors since June 2007. He is a proven leader with more than 20 years of financial management experience. We believe that he will play an important role in our ongoing success."

Mr. Beck joins Ardea Biosciences from Metabasis Therapeutics, Inc., which he co-founded in 1999 and where he served most recently as Senior Vice President of Finance, Chief Financial Officer and Treasurer. Prior to Metabasis, he served as Director of Finance of Neurocrine Biosciences, Inc., where he played an important role in Neurocrine's 1996 initial public offering. Prior to joining Neurocrine, Mr. Beck held financial management positions at various high technology and financial services companies, including General Dynamics and Ernst and Young LLP. Mr. Beck received a B.A. in accounting from the University of Washington and also holds a Th.B. in theology from a Seattle, Washington-based seminary. Mr. Beck is a licensed (inactive status) certified public accountant in the state of California and is a member of the American Institute of Certified Public Accountants and the Association of Bioscience Financial Officers.

Recent Accomplishments

In the first quarter of 2008, we continued to progress our development pipeline in all three therapeutic areas of focus, including:

-- Announced positive preliminary results for RDEA806, our lead non-

nucleoside reverse transcriptase inhibitor (NNRTI), in a Phase 2a

monotherapy study in patients with human-immunodeficiency virus (HIV),

demonstrating an up to 2.0 log placebo-adjusted reduction in plasma

viral load after seven days of treatment;

-- Completed a first-in-human micro-dosing study of our second generation

NNRTI, RDEA427, and selected it as a development candidate;

-- Completed a first-in-human micro-dosing study of our second generation

MEK inhibitor, RDEA436, and selected it as a development candidate;

-- Presented preclinical data demonstrating potent activity and favorable

resistance profiles for our next generation NNRTI family of compounds

against HIV at the 15th Annual Conference on Retroviruses and

Opportunistic Infections (CROI) and the 21st International Conference

on Antiviral Research (ICAR);

-- Presented preclinical data demonstrating the potent activity and

favorable pharmacokinetic profile of our mitogen-activated ERK kinase

(MEK) inhibitor family of compounds in the treatment of cancer,

preliminary Phase 1 data demonstrating the potential for once-daily

oral dosing of RDEA119, our lead MEK inhibitor, and first-in-human

micro-dose data for RDEA436, at the American Association for Cancer

Research (AACR);

-- Established two scientific advisory boards to guide the HIV and

inflammation programs; and

-- Relocated our corporate headquarters and research laboratories to San

Diego's biotechnology corridor.

2008 1st Quarter Financial Results

As of March 31, 2008, the Company had $56.2 million in cash, cash equivalents and short-term investments, compared to $66.2 million as of December 31, 2007.

The net loss for the first quarter ended March 31, 2008 was $12.4 million, or $0.93 per share, compared to a net loss for the same period in 2007 of $3.4 million, or $0.37 per share. The net loss included non-cash stock-based compensation expense of $1.0 million, or $0.08 per share, and $0.2 million, or $0.02 per share, for the three months ended March 31, 2008 and March 31, 2007, respectively. The increase in net loss between these two periods was primarily due to increased expenses resulting from our continued progress with our preclinical and clinical drug candidates.

Revenue for the first quarter was $0.3 million, compared to $0.9 million for the same period in 2007. The decrease is the result of fewer research activities performed by us under our master services agreement with Valeant Pharmaceuticals ("Valeant"). Due to changing priorities at Valeant, we do not anticipate any additional research activities to be conducted under the master services agreement.

2008 Financial Guidance

The Company confirmed its financial guidance for the full year ending December 31, 2008. Excluding any funds that Ardea may receive from future business development activities, the Company anticipates 2008 net cash usage to be between $45 million and $50 million.

About Ardea Biosciences

Ardea Biosciences, Inc. of San Diego, California, is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of HIV, cancer and inflammatory diseases, including gout. We have four drug candidates in clinical trials and several others in preclinical development and discovery. Our most advanced drug candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. We have evaluated our second generation NNRTI, RDEA427, for the treatment of HIV in a human micro-dose pharmacokinetic study and have selected it as a development candidate. We are also investigating RDEA806 for the treatment of gout. We are evaluating our lead MEK inhibitor, RDEA119, in a Phase 1 study in advanced cancer patients, as well as in a Phase 1 study in normal healthy volunteers for the treatment of inflammatory diseases. We have evaluated our second generation MEK inhibitor, RDEA436, for the treatment of cancer and inflammatory diseases in a human micro-dose pharmacokinetic study, and have selected it as a development candidate. In addition to the foregoing clinical programs, we are investigating other drug candidates in earlier stages of preclinical development and discovery.

(Financial Tables Follow)


(formerly IntraBiotics Pharmaceuticals, Inc.)


(In thousands, except per share data)


Three Months Ended

March 31

2008 2007

Collaboration Revenues $260 $893

Operating Expenses:

Research and Development 9,745 3,513

General and Administrative 3,632 1,544

Total Operating Expenses 13,377 5,057

Operating Loss: (13,117) (4,164)

Interest Income 607 611

Other Income 135 184

Net loss $(12,375) $(3,369)

Non-cash dividends on Series A

Preferred stock (60) (60)

Net loss applicable to common

shareholders $(12,435) $(3,429)

Basic and diluted net loss per

share applicable to common

stockholders $(0.93) $(0.37)

Shares used to compute basic and

diluted net loss per share

applicable to common stockholders 13,337 9,373

Condensed Balance Sheet Data

(In Thousands)

March 31 December 31

2008 2007

Cash, cash equivalents and short-

term investments 56,164 66,215

Total assets 59,368 68,840

Total stockholders' equity 52,839 63,739

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: sufficiency of cash resources and our goals, including the expected properties and benefits of RDEA806, RDEA427, RDEA119, RDEA436 and our other compounds and the results of preclinical, clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, and costs associated with internal development and business development activities. These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
9. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
10. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
11. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
Post Your Comments:
(Date:4/1/2020)... ... ... Care Station Medical Group -- In light of the rise of novel ... care for our community. As New Jersey's leading urgent care and primary care providers, ... medical care to patients coping with COVID-19. , "Our infectious disease clinic is ...
(Date:4/1/2020)... (PRWEB) , ... April 01, 2020 , ... ... has begun producing reusable face shields. As large manufacturers nation-wide scramble to retool ... make do reusing masks or in extreme cases, using hand-sewn masks to protect ...
(Date:3/30/2020)... ... March 30, 2020 , ... FastMed Urgent Care , ... self-assessment tool on . FastMed is offering its COVID-19 self-assessment tool as ... care based on a brief series of questions that help assess the risk of ...
Breaking Medicine Technology:
(Date:4/2/2020)... ... 2020 , ... The Northern Virginia Community College Educational Foundation (NOVA Foundation) is ... of Palm Beach, Florida. Ms. Howe is adding to her existing endowed scholarship ... more important than ever given the current pandemic. Ms. Howe has also generously donated ...
(Date:4/1/2020)... , ... April 02, 2020 , ... Medical Device Change ... EDT, , What change management method should one be using ... is often dependent on the type of change. Is it due to post-market design ...
(Date:4/1/2020)... ... April 01, 2020 , ... Global mobile data platform provider Zerion Software announced ... new needs based on COVID-19. , As cases continue to rise across the world, ... Zerion will extend support by offering free basic iFormBuilder accounts and forms - including ...
(Date:3/28/2020)... ... March 27, 2020 , ... Suntuity AirWorks ( ... companies, is mobilizing their drone equipment and training personnel to help towns and ... Enterprise level Matrice and Agras drones, Suntuity AirWorks is mobilizing their drone equipment ...
(Date:3/28/2020)... (PRWEB) , ... March 27, 2020 , ... ... announces the launch of this March’s edition of “The Fertility Journey.” This campaign ... face of fertility, third-party parenting, and maternal health options. , One in ...
Breaking Medicine News(10 mins):